Pharmaceutical Industry

STAT Q&A
Biotech

Q&A: How biotech analysts navigate fickle markets, pushy investors, and ‘vindictive’ CEOs

By Adam Feuerstein and Damian Garde

Lamar Alexander
Politics

House poised to pass bill critical for drug industry; the Senate may be a slog

By Erin Mershon

Donald Trump
Politics

Under fire from Trump, drug industry lands Oval Office meeting on Tuesday

By Dylan Scott

Handshake merger
Biotech

Biopharma expects a lot of M&A this year

By Meghana Keshavan

Trump and pharma
Politics

The drug industry’s stake in Trumpcare is bigger than you think

By Dylan Scott

Heather Bresch, Doug Throckmorton Mylan
Business

Drug prices don’t budge even after pressure from Congress

By Associated Press

Pharma needs new Prescription
First Opinion

Election verdict: Pharma needs a new prescription

By Dana Goldman and Darius Lakdawalla

Donald Trump
Politics

Big Pharma’s big question: Is Trump friend or foe?

By Dylan Scott

Voting California
Politics

Prop 61: Californians appear to say no to lowering drug costs

By Rebecca Robbins

Proposition 61
Politics

Drug pricing fight in California turns nasty with ads tarring pharma execs as criminals

By Rebecca Robbins and Meghana Keshavan

Proposition 61 - pharmalot
The Pharmalot View

Californians can sock it to ‘greedy’ pharma. But will ballot vote bring down drug prices?

By Ed Silverman

Richard Burr
Politics

In a tight race, one of pharma’s favorite senators gets a little help from his friends

By Sheila Kaplan

antimicrobial resistance
First Opinion

Waste from pharmaceutical plants in India and China promotes antibiotic-resistant superbugs

By Henry A. Waxman and Bill Corr

Aloquin
Pharmalot

The curious case of the $9,500 skin gel

By Ed Silverman

Heather Bresch
Business

The EpiPen was her ‘baby.’ Now this pharma CEO is in the hot seat over price hikes

By Damian Garde

Donald Trump sign
Politics

Donald Trump’s trade talk is making the drug industry uneasy

By Dylan Scott

Dollars
Politics

5 ways drug makers and the health care industry are shaping campaigns

By Sheila Kaplan

Brazil Zika microcephaly
In the Lab

The race for a Zika vaccine is intense. But it may be missing the most important players

By Helen Branswell

CEO Biotech trading
Don't Miss

How biotech executives profit from legal insider trades

By Damian Garde

David Vetter Bubble Boy 1977
Biotech

There’s a possible cure for ‘bubble boy’ disease. It will cost $665,000

By Damian Garde

Pharmacy Benefit Managers
The Pharmalot View

The ‘gouge factor’: Big companies want transparency in drug price negotiations

By Ed Silverman

Pfizer Ad
Business

Why Democratic convention viewers saw so many drug ads

By Rebecca Robbins

Trump
First Opinion

Say what you will about Donald Trump. He’s right about drug companies

By Charles D. Rosen

Mark Cuban
Don't Miss

Billionaire businessman Mark Cuban has something to say about drug prices

By Dylan Scott

Acetylcholine receptor
Biotech

Could a molecular ‘on-off switch for agony’ lead to a safer painkiller?

By Damian Garde

Hospitals Corridor
Business

Drug and device makers find receptive audience at for-profit, Southern hospitals

By Charles Ornstein and Ryann Grochowski Jones — ProPublica

Drug Industry Overstates Patents
The Pharmalot View

Drug industry overstates impact of patent reviews on innovation

By Ed Silverman

Brexit
Biotech

Post-Brexit, will the European Medicines Agency be homeless?

By Meghana Keshavan and Rebecca Robbins

Supreme Court
Politics

Supreme Court’s ruling in patent case a blow to drug industry

By Dylan Scott

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy